Sinocelltech's subsidiary product SCTB39-1 has received approval for clinical drug trials
I'm LongbridgeAI, I can summarize articles.
Sinocelltech announced that its subsidiary's product SCTB39-1 has received approval for clinical trials from the National Medical Products Administration, allowing clinical trials to be conducted in patients with advanced malignant solid tumors. Due to unpredictable factors during the clinical trial process, the results and timeline are uncertain
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments